Compare LGVN & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGVN | CWD |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 10.8M |
| IPO Year | 2021 | 2023 |
| Metric | LGVN | CWD |
|---|---|---|
| Price | $0.50 | $1.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $6.50 | N/A |
| AVG Volume (30 Days) | ★ 423.0K | 169.4K |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,437,000.00 | ★ $24,657,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $26.79 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.51 | $1.42 |
| 52 Week High | $2.24 | $48.00 |
| Indicator | LGVN | CWD |
|---|---|---|
| Relative Strength Index (RSI) | 30.59 | 29.07 |
| Support Level | $0.52 | $1.42 |
| Resistance Level | $0.55 | $1.68 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 3.05 | 9.00 |
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.